Cargando…

Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours

BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Guohui, Wang, Chunbo, He, Yunlong, E, Mingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819520/
https://www.ncbi.nlm.nih.gov/pubmed/31661009
http://dx.doi.org/10.1186/s40360-019-0362-2
_version_ 1783463750372687872
author Liu, Guohui
Wang, Chunbo
He, Yunlong
E, Mingyan
author_facet Liu, Guohui
Wang, Chunbo
He, Yunlong
E, Mingyan
author_sort Liu, Guohui
collection PubMed
description BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumours. The aim of this study was to investigate the efficacy of apatinib in patients with advanced malignant tumours and failure of standard therapy. METHODS: We collected 41 patients with advanced malignant tumours in our department; all tumours were pathologically confirmed as malignant. All patients received apatinib after failure of standard therapy: 500 mg/dose, one dose/d, orally 30 min after a meal, until progressive disease or intolerable adverse reactions occurred. When there was a second- or third-degree adverse reaction associated with apatinib during treatment, apatinib treatment could be suspended or reduced to 250 mg/dose. Clinical efficacy and progression-free survival were assessed according to RECIST1.1, and adverse reactions were observed. RESULTS: Efficacy assessment was available for 31 patients with a median progression-free survival time of 2.66 months; the objective response rate and disease control rates were 16.1 and 64.5%, respectively. The disease control rates of the patients with lower Eastern Cooperative Oncology Group scores (1–2 points) and with fewer metastatic sites (< 3 sites) were higher than those of the patients with higher scores (3 points) and with more metastatic sites (≥3 sites), respectively (all P < 0.05). The most common adverse reactions were hypertension, neutropenia and hand-foot syndrome. CONCLUSION: For patients with advanced malignant tumours with failure of standard therapy, administration of apatinib can still result in good efficacy. The efficacy of apatinib is better in patients with a higher performance status and lower degree of tumour progression.
format Online
Article
Text
id pubmed-6819520
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68195202019-10-31 Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours Liu, Guohui Wang, Chunbo He, Yunlong E, Mingyan BMC Pharmacol Toxicol Research Article BACKGROUND: In recent years, targeted therapy has received widespread attention. Among these therapies, anti-angiogenic targeted drugs have become one of the hotspots of research. Apatinib is a novel oral small molecule anti-angiogenic agent that has been clinically tested in a variety of solid tumours. The aim of this study was to investigate the efficacy of apatinib in patients with advanced malignant tumours and failure of standard therapy. METHODS: We collected 41 patients with advanced malignant tumours in our department; all tumours were pathologically confirmed as malignant. All patients received apatinib after failure of standard therapy: 500 mg/dose, one dose/d, orally 30 min after a meal, until progressive disease or intolerable adverse reactions occurred. When there was a second- or third-degree adverse reaction associated with apatinib during treatment, apatinib treatment could be suspended or reduced to 250 mg/dose. Clinical efficacy and progression-free survival were assessed according to RECIST1.1, and adverse reactions were observed. RESULTS: Efficacy assessment was available for 31 patients with a median progression-free survival time of 2.66 months; the objective response rate and disease control rates were 16.1 and 64.5%, respectively. The disease control rates of the patients with lower Eastern Cooperative Oncology Group scores (1–2 points) and with fewer metastatic sites (< 3 sites) were higher than those of the patients with higher scores (3 points) and with more metastatic sites (≥3 sites), respectively (all P < 0.05). The most common adverse reactions were hypertension, neutropenia and hand-foot syndrome. CONCLUSION: For patients with advanced malignant tumours with failure of standard therapy, administration of apatinib can still result in good efficacy. The efficacy of apatinib is better in patients with a higher performance status and lower degree of tumour progression. BioMed Central 2019-10-28 /pmc/articles/PMC6819520/ /pubmed/31661009 http://dx.doi.org/10.1186/s40360-019-0362-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Guohui
Wang, Chunbo
He, Yunlong
E, Mingyan
Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title_full Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title_fullStr Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title_full_unstemmed Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title_short Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
title_sort application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819520/
https://www.ncbi.nlm.nih.gov/pubmed/31661009
http://dx.doi.org/10.1186/s40360-019-0362-2
work_keys_str_mv AT liuguohui applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours
AT wangchunbo applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours
AT heyunlong applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours
AT emingyan applicationeffectofapatinibinpatientswithfailureofstandardtreatmentforadvancedmalignanttumours